The application value of IVIM-DWI for diagnosing and differentiating pancreatic cancer and neuroendocrine tumor

MA Wan-ling; ZHAO Wei-wei; HUAN Yi; WEI Meng-qi; REN Jing; YANG Yong; ZHANG Jin-song; PAN Qi; ZHANG Guang-wen; DONG Jun-qiang

Journal of China Clinic Medical Imaging ›› 2017, Vol. 28 ›› Issue (1) : 49-54.

MA Wan-ling, ZHAO Wei-wei, HUAN Yi, WEI Meng-qi, REN Jing, YANG Yong, ZHANG Jin-song,PAN Qi, ZHANG Guang-wen, DONG Jun-qiang

Author information +

History +

Abstract

Objective: To explore the optimal quantitative parameters obtained from IVIM-DWI for diagnosing and differentiating pancreatic cancer and neuroendocrine tumor. Methods: Subjects comprised 22 patients with pancreatic cancer and 17 patients with pancreatic neuroendocrine tumors, All the patients were confirmed by surgery. Pancreas multiple b value DWI was performed using GE Discovery MR750 3.0T scanner. Apparent diffusion coefficient(ADC), pure diffusion constant(D), pseudodiffusion coefficient(D*) and perfusion fraction(f) were calculated by using IVIM model. Parameters obtained from IVIM-DWI were tested by One-Way ANOVA. Results: ADC and f values of pancreatic cancer were lower than non-cancerous pancreatic tissue(0.803×10-3 mm2/s vs 0.974×10-3 mm2/s; 54.527% vs 64.486%, respectively). D of pancreatic cancer was higher than non-cancerous pancreatic tissue(0.659×10-3 mm2/s vs 0.535×10-3 mm2/s). D is superior to ADC and f for the differentiation between pancreatic cancer and non-cancerous pancreas. ADC, D and f values of pancreatic neuroendocrine tumor were higher than non-tumorous pancreatic tissue(0.933×10-3 mm2/s vs 0.753×10-3 mm2/s; 0.549×10-3 mm2/s vs 0.429×10-3 mm2/s; 67.275% vs 59.655%, respectively). ADC is superior to D and f for the differentiation between pancreatic neuroendocrine tumor and non-tumorous pancreas. ADC, D* and f values of pancreatic cancer were lower than pancreatic neuroendocrine tumor(0.803×10-3 mm2/s vs 0.933×10-3 mm2/s; 4.852×10-3 mm2/s vs 11.301×10-3 mm2/s; 54.527% vs 67.275%, respectively). D* is superior to ADC and f for the differentiation between pancreatic cancer and neuroendocrine tumor. D* value of pancreatic cancer was significantly lower than G2～3 grade pancreatic neuroendocrine tumor(4.852×10-3 mm2/s vs 11.937×10-3 mm2/s). Conclusion: Quantitative parameters ADC, D, D* and f obtained from IVIM-DWI can diagnose and differentiate pancreatic cancer, neuroendocrine tumor and non-cancerous pancreatic tissue. IVIM-DWI may be a promising and non-invasive tool for diagnosing and differentiating pancreatic carcinoma and neuroendocrine tumor.

Key words

Pancreatic neoplasms / Carcinoma, neuroendocrine / Diffusion magnetic resonance imaging

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

MA Wan-ling, ZHAO Wei-wei, HUAN Yi, WEI Meng-qi, REN Jing, YANG Yong, ZHANG Jin-song,PAN Qi, ZHANG Guang-wen, DONG Jun-qiang. The application value of IVIM-DWI for diagnosing and differentiating pancreatic cancer and neuroendocrine tumor[J]. Journal of China Clinic Medical Imaging. 2017, 28(1): 49-54

References

[1]Waghraya M, Yalamanchilia M, Magliano MP, et al. Deciphering the role of stroma in pancreatic cancer[J]. Curr Opin Gastroenterol, 2013, 29(5): 537-543.
[2]Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma [J]. N Engl J Med, 1992, 326(7): 455-465.
[3]Klimstra DS, Pitman MB, Hruban RN. An algorithmic approach to the diagnosis of pancreatic neoplasms[J]. Arch Pathol Lab Med, 2009, 133(3): 454-464.
[4]Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update[J]. Curr Treat Options Oncol, 2012, 13(1): 24-34.
[5]王佳，钟燕，王海屹，等. 胰腺神经内分泌癌患者的磁共振影像诊断特征分析[J]. 中华医学杂志，2012，92（7）：483-486.
[6]Philips S, Shah SN, Vikram R, et al. Pancreatic endocrine neoplasms: a current update on genetics and imaging[J]. Br J Radiol, 2012, 85(1014): 682-696.
[7]Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors[J]. Ann Surg, 1996, 223(3): 273-279.
[8]Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen(CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer[J]. Eur J Surg Oncol, 2007, 33(3): 266-270.
[9]王洪江，邵本深，赵作伟. 术中Tm-cut型针活检对胰腺肿块的诊断价值[J]. 中国普通外科杂志，2005，14（5）：399-400.
[10]Kinney TP, Freeman ML. Recent advances and novel methods in pancreatic imaging[J]. Minerva Gastroenterol Dietol, 2008, 54(1): 85-95.
[11]Brenner R, Metens T, Bali M, et al. Pancreatic neuroendocrine tumor: added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection[J]. Eur J Radiol, 2012, 81(5): 746-749.
[12]Jang KM, Kim SH, Lee SJ, et al. The value of gadoxetic acid-enhanced and diffusion-weighted MRI for prediction of grading of pancreatic neuroendocrine tumors[J]. Acta Radiol, 2014, 55(2): 140-148.
[13]Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, et al. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas[J]. Eur J Nucl Med Mol Imaging, 2013, 40(6): 897-907.
[14]Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology[J]. AJR, 2007, 188(6): 1622-1635.
[15]Le Bihan D, Breton E, Lallemand D, et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders[J]. Radiology, 1986, 161(2): 401-407.
[16]Le Bihan D, Breton E, Lallemand D, et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging[J]. Radiology, 1988, 168(2): 497-505.
[17]Le Bihan D, Turner R, Moonen CT, et al. Imaging of diffusion and microcirculation with gradient sensitization: design, strategy, and significance[J]. J Magn Reson Imaging, 1991, 1(1): 7-28.
[18]Le Bihan D. IVIM method measures diffusion and perfusion[J]. Diagn Imaging(San Franc), 1990, 12(6): 133-136.
[19]Muraoka N, Uematsu H, Kimura H, et al. Apparent diffusion coefficient in pancreatic cancer: characterization and histopathological correlations[J]. J Magn Reson Imaging, 2008, 27(6): 1302-1308.
[20]Yoshikawa T, Kawamitsu H, Mitchell DG, et al. ADC measurement of abdominal organs and lesions using parallel imaging technique[J]. AJR, 2006, 187(6): 1521-1530.
[21]Lemke A, Laun FB, Klauss M, et al. Differentiation of pancreas carcinoma from healthy pancreatic tissue using multiple b-values: comparison of apparent diffusion coefficient and intravoxel incoherent motion derived parameters[J]. Invest Radiol, 2009, 44(12): 769-775.
[22]Semelka RC, Custodio CM, Cem Balci N, et al. Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI[J]. J Magn Reson Imaging, 2000, 11(2): 141-148.
[23]Gabata T, Matsui O, Kadoya M, et al. Small pancreatic adenocarcinomas: efficacy of MR imaging with fat suppression and gadolinium enhancement[J]. Radiology, 1994, 193(3): 683-688.
[24]Worhunsky DJ, Krampitz GW, Poullos PD, et al. Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness[J]. HPB(Oxford), 2014, 16(4): 304-311.
[25]Kloppel G, Heitz PU. Pancreatic endocrine tumors[J]. Pathol Res Pract, 1988, 183(2): 155-168.
[26]Sutliff VE, Doppman JL, Gibril F, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns[J]. J Clin Oncol, 1997, 15(6): 2420-2431.